肝细胞肝癌相关基因拷贝数变异的研究
|
摘要
背景和目的肝细胞肝癌(HCC)是常见的恶性肿瘤之一。我国HCC病人多有肝炎背景。乙型肝炎病毒感染导致的HCC具有非常明显的家族聚集性和遗传易感性,其发病率呈患者一级亲属、二级亲属递减,且均高于群体发病率。因此从基因水平研究肝癌的易感机制十分必要。从基因转录水平对HCC的发病机制进行研究目前已经有很多报道。近年来从基因组结构变异水平对拷贝数变异(copy number variations, CNVs)与疾病的关联进行研究逐渐成为热点。CNVs是指与基因组参考序列相比,基因组中≥1 kb的DNA片段插入、缺失和／或扩增。人类基因组CNVs图谱提示在研究与疾病相关的基因变异时必须考虑CNVs,否则会错过重要的信息。因此本研究的主要目的是在基因组结构水平上找到与肝炎病毒所致HCC发病机制密切相关的CNVs,并结合临床病理学资料进行预后分析,以期为HCC诊治和预后提供新的思路。
方法我们通过SNP芯片对25例HCC患者的样本进行配对的全基因组检测,初步获得与HCC发病机制相关的基因CNVs结果。继之结合相关资料,进一步筛选出与肝炎所致HCC相关的候选基因,通过实时定量PCR检测后者在肝癌组织和癌旁组织中的拷贝数,明确候选基因是否存在CNVs。同时我们收集患者的临床病理学资料,并结合相关基因进行预后分析,进一步明确相关基因的CNVs是否与重要的临床病理因素相联系。
结果比较患者的肝癌组织与其血液标本的基因表达谱,共得到1854个差异基因,其中上调基因1242个,下调基因612个,提示仅有少数基因参与肿瘤细胞的癌变过程。我们继之筛选出与JAK-STAT通路相关的五个基因：STAT3.STAT2、STAT4、JAK1、IL-6以及近来较多关注的Lin-28B进行研究。实时定量PCR检测结果显示HCC组织中STAT3的拷贝数显著高于相应的癌旁组织(P＜0.05)；HCC组织中STAT2、STAT4、JAK1、IL-6和Lin-28B的拷贝数与相应癌旁组织相比无显著增高(P＞0.05)。继之,我们比较每例患者HCC组织与癌旁组织的JAK1拷贝数差异,并据此将患者分为两组,一组患者HCC组织中JAK1的拷贝数比癌旁组织高,另一组相比较低。生存分析提示JAK1对患者术后的累积生存率没有显著影响(P＞0.05)。并且,术前的AFP水平、术前ALT水平、术前AST水平、肿瘤直径、分化程度、肿瘤个数在两组间的分布无统计学差异(P＞0.05)。对另一基因STAT4进行分析,与JAK1的统计结果相同(P＞0.05)。40例HCC患者的1、3年生存率分别为87.2%、67.9%。单因素分析发现影响患者术后累积生存率的因素包括术前AFP水平、肿瘤个数以及分化程度(P＜0.05)；多因素分析提示影响患者术后累积生存率的独立危险因素包括肿瘤个数及分化程度(P＜0.05)
结论STAT3的拷贝数在HCC组织及癌旁组织中存在显著差异,提示STAT3的CNVs在HCC的发病机制中有重要作用；JAK1和STAT4的CNVs对于HCC患者的术后累积生存率以及相关的临床病理因素没有显著影响；肿瘤个数及分化程度是影响HCC预后的独立因素,术前AFP水平是影响预后的重要因素。
Background & Aims Hepatocellular Carcinoma (HCC) is one of the most common malignant tumor in the world. Most patients with HCC have chronic hepatitis in China. Significantly, HCC which results from chronic B hepatitis virus (HBV) has familial aggregation and genetic susceptibility, and the incidence of HCC which are correlative with the first and the second degree relative decreased progressively, furthermore, the incidence were high than population risk respectively. Therefore, it is necessary to study the susceptible mechanism of HCC related to genome-wide abnormalities. Now there were lots of studies about the susceptible mechanism of HCC at transcriptional level. Recently, the studies focus on the genome-wide study of association between CNVs and diseases at the level of DNA structural variation. CNVs are the result of duplications, deletions, insertions, inversions and complex combinations of rearrangements, and is defined as a chromosomal segment that is 1kb or larger in length, whose copy number varied in comparison to a reference genome. In a recent study CNVs have been mapped, and scientists found that genomic regions containing CNV may harbor important genes and gene regulatory elements, and may have considerable influence on disease susceptibility. Thus, we attempt to find CNVs related to carcinogenesis of HCC result from hepatitis virus infection at the level of genomic structure abnormalities, and analyze the clinico-pathological data of HCC patients after surgical resection, which may provide new path to favor the diagnosis, treatment and prognosis of HCC.
Methods We screened CNVs in 25 patients with HCC by the high-resolution SNP arrays, and gained preliminary data. Then, we selected certain gene which is important in the carcinogenesis of HCC result from hepatitis virus infection, and identified the existence of CNVs by detecting the copy number of selected genes in the HCC tissue and peri-carcinomatous tissue. At the same time, we collected the clinic-pathological data of HCC patients to analyze the relationships between the prognosis of patients and the CNVs of certain genes.
Results There were 1854 CNVs by screening the HCC tissue and peri-carcinomatous tissue using SNP arrays. We find 1242 CNVs with up-regulation and 612 CNVs with down-regulation, which indicates only a little of genes take part in the progression of malignant transformation. We selected Lin-28B gene which was noticeable in the present studies and five genes relevant to JAK-STAT pathway including STAT3、STAT2、STAT4、JAK1、IL-6. The results of real-time PCR showed that the copy number of
STAT3 was higher in HCC tissue than in peri-carcinomatous tissue(P<0.05), and the copy numbers of STAT2、STAT4、JAK1、IL-6、Lin-28B had no significant difference between two groups (P>0.05). Then we divided patients into two groups. The copy numbers of JAK1 were higher in HCC tissue than in peri-carcinomatous tissue in group 1 and lower in group 2. Survival analysis showed that JAK1 didn't impact the prognosis of HCC patients after operation (P>0.05). Furthermore, tumor size, differentiation and the preoperative level of AFP, ALT, and AST had no significant difference between two groups (P>0.05).The analysis of STAT4 showed the same results as that of JAK1 (P >0.05). The overall 1-,3-year survival rates were 82.7%and 67.9%, respectively. Univariate analysis showed that tumor number, differentiation and preoperative level of AFP were significant factors affecting the survival(P<0.05). Multivariate analysis demonstrated that tumor number and differentiation were the independent factors affecting the survival(P<0.05).
Conclusion The copy number of STAT3 was higher in HCC tissue than in peri-carcinomatous tissue, which shows that the CNVs of STAT3 play an important role in the carcinogenesis of HCC result from hepatitis virus infection. The CNVs of JAK1 and STAT4 didn't impact the prognosis and some clinico-pathological factors of HCC patients after operation. Tumor number and differentiation were the independent factors affecting the survival. The preoperative level of AFP is an important prognostic factor for the surgical management.
方法我们通过SNP芯片对25例HCC患者的样本进行配对的全基因组检测,初步获得与HCC发病机制相关的基因CNVs结果。继之结合相关资料,进一步筛选出与肝炎所致HCC相关的候选基因,通过实时定量PCR检测后者在肝癌组织和癌旁组织中的拷贝数,明确候选基因是否存在CNVs。同时我们收集患者的临床病理学资料,并结合相关基因进行预后分析,进一步明确相关基因的CNVs是否与重要的临床病理因素相联系。
结果比较患者的肝癌组织与其血液标本的基因表达谱,共得到1854个差异基因,其中上调基因1242个,下调基因612个,提示仅有少数基因参与肿瘤细胞的癌变过程。我们继之筛选出与JAK-STAT通路相关的五个基因：STAT3.STAT2、STAT4、JAK1、IL-6以及近来较多关注的Lin-28B进行研究。实时定量PCR检测结果显示HCC组织中STAT3的拷贝数显著高于相应的癌旁组织(P＜0.05)；HCC组织中STAT2、STAT4、JAK1、IL-6和Lin-28B的拷贝数与相应癌旁组织相比无显著增高(P＞0.05)。继之,我们比较每例患者HCC组织与癌旁组织的JAK1拷贝数差异,并据此将患者分为两组,一组患者HCC组织中JAK1的拷贝数比癌旁组织高,另一组相比较低。生存分析提示JAK1对患者术后的累积生存率没有显著影响(P＞0.05)。并且,术前的AFP水平、术前ALT水平、术前AST水平、肿瘤直径、分化程度、肿瘤个数在两组间的分布无统计学差异(P＞0.05)。对另一基因STAT4进行分析,与JAK1的统计结果相同(P＞0.05)。40例HCC患者的1、3年生存率分别为87.2%、67.9%。单因素分析发现影响患者术后累积生存率的因素包括术前AFP水平、肿瘤个数以及分化程度(P＜0.05)；多因素分析提示影响患者术后累积生存率的独立危险因素包括肿瘤个数及分化程度(P＜0.05)
结论STAT3的拷贝数在HCC组织及癌旁组织中存在显著差异,提示STAT3的CNVs在HCC的发病机制中有重要作用；JAK1和STAT4的CNVs对于HCC患者的术后累积生存率以及相关的临床病理因素没有显著影响；肿瘤个数及分化程度是影响HCC预后的独立因素,术前AFP水平是影响预后的重要因素。
Background & Aims Hepatocellular Carcinoma (HCC) is one of the most common malignant tumor in the world. Most patients with HCC have chronic hepatitis in China. Significantly, HCC which results from chronic B hepatitis virus (HBV) has familial aggregation and genetic susceptibility, and the incidence of HCC which are correlative with the first and the second degree relative decreased progressively, furthermore, the incidence were high than population risk respectively. Therefore, it is necessary to study the susceptible mechanism of HCC related to genome-wide abnormalities. Now there were lots of studies about the susceptible mechanism of HCC at transcriptional level. Recently, the studies focus on the genome-wide study of association between CNVs and diseases at the level of DNA structural variation. CNVs are the result of duplications, deletions, insertions, inversions and complex combinations of rearrangements, and is defined as a chromosomal segment that is 1kb or larger in length, whose copy number varied in comparison to a reference genome. In a recent study CNVs have been mapped, and scientists found that genomic regions containing CNV may harbor important genes and gene regulatory elements, and may have considerable influence on disease susceptibility. Thus, we attempt to find CNVs related to carcinogenesis of HCC result from hepatitis virus infection at the level of genomic structure abnormalities, and analyze the clinico-pathological data of HCC patients after surgical resection, which may provide new path to favor the diagnosis, treatment and prognosis of HCC.
Methods We screened CNVs in 25 patients with HCC by the high-resolution SNP arrays, and gained preliminary data. Then, we selected certain gene which is important in the carcinogenesis of HCC result from hepatitis virus infection, and identified the existence of CNVs by detecting the copy number of selected genes in the HCC tissue and peri-carcinomatous tissue. At the same time, we collected the clinic-pathological data of HCC patients to analyze the relationships between the prognosis of patients and the CNVs of certain genes.
Results There were 1854 CNVs by screening the HCC tissue and peri-carcinomatous tissue using SNP arrays. We find 1242 CNVs with up-regulation and 612 CNVs with down-regulation, which indicates only a little of genes take part in the progression of malignant transformation. We selected Lin-28B gene which was noticeable in the present studies and five genes relevant to JAK-STAT pathway including STAT3、STAT2、STAT4、JAK1、IL-6. The results of real-time PCR showed that the copy number of
STAT3 was higher in HCC tissue than in peri-carcinomatous tissue(P<0.05), and the copy numbers of STAT2、STAT4、JAK1、IL-6、Lin-28B had no significant difference between two groups (P>0.05). Then we divided patients into two groups. The copy numbers of JAK1 were higher in HCC tissue than in peri-carcinomatous tissue in group 1 and lower in group 2. Survival analysis showed that JAK1 didn't impact the prognosis of HCC patients after operation (P>0.05). Furthermore, tumor size, differentiation and the preoperative level of AFP, ALT, and AST had no significant difference between two groups (P>0.05).The analysis of STAT4 showed the same results as that of JAK1 (P >0.05). The overall 1-,3-year survival rates were 82.7%and 67.9%, respectively. Univariate analysis showed that tumor number, differentiation and preoperative level of AFP were significant factors affecting the survival(P<0.05). Multivariate analysis demonstrated that tumor number and differentiation were the independent factors affecting the survival(P<0.05).
Conclusion The copy number of STAT3 was higher in HCC tissue than in peri-carcinomatous tissue, which shows that the CNVs of STAT3 play an important role in the carcinogenesis of HCC result from hepatitis virus infection. The CNVs of JAK1 and STAT4 didn't impact the prognosis and some clinico-pathological factors of HCC patients after operation. Tumor number and differentiation were the independent factors affecting the survival. The preoperative level of AFP is an important prognostic factor for the surgical management.
引文
Aaronson DS, Horvath CM.2002. A road map for those who don't know JAK-STAT. Science. 296(5573):1653-5.
Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al.2009. Signal transducer and activator of transcription-3, inflammation, and cancer:how intimate is the relationship. Ann N Y Acad Sci. 1171:59-76.
Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB.2008. Guggulsterone, a famesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res.68(11):4406-15.
Ahuja SK, Kulkarni H, Catano G, et al.2008. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med.14(4): 413-20.
Aitman TJ, Dong R, Vyse TJ, et al.2006. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature.439(7078):851-5.
Aoki Y, Feldman GM, Tosato G.2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood.101(4):1535-42.
Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA.2006. Receptor-mediated tobacco toxicity:cooperation of the Ras/Raf-1/MEKl/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J.20(12):2093-101.
Banninger G, Reich NC.2004. STAT2 nuclear trafficking. J Biol Chem.279(38):39199-206.
Bao BY, Hu YC, Ting HJ, Lee YF.2004. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene.23(19):3350-60.
Bharti AC, Shishodia S, Reuben JM, et al.2004. Nuclear factor-kappaB and STAT3 are constitutively active in CD 138+cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood.103(8):3175-84.
Bhattacharya S, Schindler C.2003. Regulation of Stat3 nuclear export. J Clin Invest.111(4):553-9.
Bianchini F, Mannini A, Mugnai G, Ruggieri S, Calorini L.2006. Expression of a metastatic phenotype in IFNs-primed/TNFalpha-activated B16 murine melanoma cells:role of JAKl/PKCdelta signal transduction factors. Clin Exp Metastasis.23(3-4):203-8.
Bluyssen AR, Durbin JE, Levy DE.1996. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev.7(1):11-7.
Boehm AL, Sen M, Seethala R, et al.2008. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol.73(6):1632-42.
Bosch FX, Ribes J, Cleries R, Diaz M.2005. Epidemiology of hepatocellular carcinoma. Clin Liver Dis.9(2):191-211.
Bot A, Rodrigo E, Wolfe T, Bot S, Von Herrath MG.2003. Infection-triggered regulatory mechanisms override the role of STAT 4 in control of the immune response to influenza virus antigens. J Virol.77(10):5794-800.
Bowman T, Garcia R, Turkson J, Jove R.2000. STATs in oncogenesis. Oncogene.19(21):2474-88.
Bromberg J, Darnell JE Jr.2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene.19(21):2468-73.
Catlett-Falcone R, Landowski TH, Oshiro MM, et al.1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity.10(1):105-15.
Chan KS, Sano S, Kataoka K, et al.2008. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene.27(8):1087-94.
Chan KS, Sano S, Kiguchi K, et al.2004. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest.114(5):720-8.
Chen L, Chan TH, Yuan YF, et al.2010. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 120(4):1178-91.
Cheng GZ, Zhang WZ, Sun M, et al.2008. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem.283(21):14665-73.
Chung CD, Liao J, Liu B, et al.1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science.278(5344):1803-5.
Chung J, Uchida E, Grammer TC, Blenis J.1997. STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 17(11):6508-16.
Cucchetti A, Piscaglia F, Grigioni AD, et al.2010. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network:A pilot study. J Hepatol.
Darnell JE Jr.1997. STATs and gene regulation. Science.277(5332):1630-5.
Darnell JE Jr, Kerr IM, Stark GR.1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science.264(5164):1415-21.
Dear PH.2009. Copy-number variation:the end of the human genome. Trends Biotechnol.27(8): 448-54.
El-Zayadi AR.2006. Heavy smoking and liver. World J Gastroenterol.12(38):6098-101.
Elinav E, Abd-Elnabi A, Pappo O, et al.2006. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol.44(3):529-36.
Estivill X, Armengol L.2007. Copy number variants and common disorders:filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet.3(10):1787-99.
Fanciulli M, Norsworthy PJ, Petretto E, et al.2007. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet.39(6):721-3.
Frank DA.2007. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251(2):199-210.
Garcia R, Yu CL, Hudnall A, et al.1997. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ.8(12):1267-76.
Gonzalez E, Kulkarni H, Bolivar H, et al.2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science.307(5714):1434-40.
Grunhage F, Nattermann J, Gressner OA, et al.2010. Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C. J Hepatol.52(2):153-9.
Guo Y, Chen Y, Ito H, et al.2006. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene.384:51-61.
Hayashi T, Kobayashi Y, Kohsaka S, Sano K 2006. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene.25(29):4016-26.
Hurles ME, Dermitzakis ET, Tyler-Smith C.2008. The functional impact of structural variation in humans. Trends Genet.24(5):238-45.
Ihle JN.1996. STATs:signal transducers and activators of transcription. Cell.84(3):331-4.
Itoh M, Murata T, Suzuki T, et al.2006. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene.25(8):1195-204.
Ivanov VN, Bhoumik A, Krasilnikov M, et al.2001. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell.7(3):517-28.
Ji J, Shi J, Budhu A, et al.2009. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med.361(15):1437-47.
Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ.2004. G-quartet oligonucleotides:a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res.64(18):6603-9.
Ju MJ, Qiu SJ, Fan J, et al.2009. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol.131(4): 498-510.
Kanda N, Seno H, Konda Y, et al.2004. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene.23(28):4921-9.
Karni R, Jove R, Levitzki A.1999. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 18(33):4654-62.
Kataoka K, Kim DJ, Carbajal S, Clifford JL, DiGiovanni J.2008. Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis.29(6):1108-14.
Kim KW, Mutter RW, Cao C, et al.2006. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther.5(11): 2659-65.
Kiuchi N, Nakajima K, Ichiba M, et al.1999. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med.189(1):63-73.
Klein C, Wustefeld T, Assmus U, et al.2005. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest.115(4):860-9.
Kleinjan DA, van HV.2005. Long-range control of gene expression:emerging mechanisms and disruption in disease. Am J Hum Genet.76(1):8-32.
Kobierski LA, Srivastava S, Borsook D.2000. Systemic lipopolysaccharide and interleukin-Ibeta activate the interleukin 6:STAT intracellular signaling pathway in neurons of mouse trigeminal ganglion. Neurosci Lett.281(1):61-4.
Komura D, Shen F, Ishikawa S, et al.2006. Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res.16(12):1575-84.
Lee JS, Chu IS, Heo J, et al.2004. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology.40(3):667-76.
Lee JS, Heo J, Libbrecht L, et al.2006. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med.12(4):410-6.
Lee JS.2008. Decoding human liver cancer signatures. Gastrointest Cancer Res.2(4 Suppl):S31-4.
Li W, Tan D, Zenali MJ, Brown RE.2010. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol.3(3): 238-43.
Liu H, Ma Y, Cole SM, et al.2003. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood.102(1):344-52.
Llovet JM, Burroughs A, Bruix J.2003. Hepatocellular carcinoma. Lancet.362(9399):1907-17.
Lou YJ, Pan XR, Jia PM, et al.2009. IRF-9/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1. Cancer Res.69(8):3673-80.
Mahboubi K, Li F, Plescia J, et al.2001. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest.81(3):327-34.
Masuda M, Suzui M, Yasumatu R, et al.2002. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res.62(12):3351-5.
McCarroll SA, Hadnott TN, Perry GH, et al.2006. Common deletion polymorphisms in the human genome. Nat Genet.38(1):86-92.
McCarroll SA, Huett A, Kuballa P, et al.2008. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet.40(9):1107-12.
McCarroll SA, Kuruvilla FG, Korn JM, et al.2008. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet.40(10):1166-74.
Neilson LM, Zhu J, Xie J, et al.2007. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer:recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol.21(9):2218-32.
Nieters A, Yuan JM, Sun CL, et al.2005. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer.103(4):740-8.
Nikitakis NG, Siavash H, Sauk JJ.2004. Targeting the STAT pathway in head and neck cancer:recent advances and future prospects. Curr Cancer Drug Targets.4(8):637-51.
Niu G, Wright KL, Huang.M, et al.2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene.21(13):2000-8.
Noda I, Fujieda S, Ohtsubo T, et al.1999. Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer.80(1):78-84.
Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC.2009. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 30(5):758-62.
Otero DC, Poli V, David M, Rickert RC.2006. Cutting edge:inherent and acquired resistance to radiation-induced apoptosis in B cells:a pivotal role for STAT3. J Immunol.177(10):6593-7.
Parkin DM, Bray F, Ferlay J, Pisani P.2005. Global cancer statistics,2002. CA Cancer J Clin.55(2): 74-108.
Piva R, Gambari R.2002. Transcription factor decoy (TFD) in breast cancer research and treatment. Technol Cancer Res Treat.1(5):405-16.
Rane SG, Reddy EP.2000. Janus kinases:components of multiple signaling pathways. Oncogene. 19(49):5662-79.
Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL.2002. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene.21(50):7611-8.
Redon R, Ishikawa S, Fitch KR, et al.2006. Global variation in copy number in the human genome. Nature.444(7118):444-54.
Rhodes DR, Yu J, Shanker K, et al.2004. ONCOMINE:a cancer microarray database and integrated data-mining platform. Neoplasia.6(1):1-6.
Rossi MR, Hawthorn L, Platt J, Burkhardt T, Cowell JK, Ionov Y.2005. Identification of inactivating mutations in the JAKl, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet.161(2):97-103.
Saito H, Masuda T, Tada S, et al.2009. Hepatocellular carcinoma in Keio affiliated hospitals-diagnosis, treatment, and prognosis of this disease. Keio J Med.58(3):161-75.
Saxena R, Voight BF, Lyssenko V, et al.2007. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science.316(5829):1331-6.
Shang D, Liu Y, Ito N, Kamoto T, Ogawa O.2007. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci.98(8):1259-64.
Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T.1999. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity.11(6): 709-19.
Shlien A, Tabori U, Marshall CR, et al.2008. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A.105(32):11264-9.
Singh N, Ebrahimi FA, Gimelbrant AA, et al.2003. Coordination of the random asynchronous replication of autosomal loci. Nat Genet.33(3):339-41.
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A.2010. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol.16(4):418-24.
Stranger BE, Forrest MS, Dunning M, et al.2007. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science.315(5813):848-53.
Suiqing C, Min Z, Lirong C.2005. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol.32(5):354-60.
Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH.2008. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature.451(7174):73-5.
Townson JR, Barcellos LF, Nibbs RJ.2002. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol.32(10):3016-26.
Vainchenker W, Dusa A, Constantinescu SN.2008. JAKs in pathology:role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol.19(4):385-93.
Verma A, Kambhampati S, Parmar S, Platanias LC.2003. Jak family of kinases in cancer. Cancer Metastasis Rev.22(4):423-34.
Viswanathan SR, Powers JT, Einhom W, et al.2009. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet.41(7):843-8.
Wang T, Niu G, Kortylewski M, et al.2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med.10(1):48-54.
Wei D, Le X, Zheng L, et al.2003. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene.22(3): 319-29.
Yao DF, Dong ZZ, Yao M.2007. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.6(3):241-7.
Yeh YT, Ou-Yang F, Chen IF, et al.2007. Altered p-JAKl expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma. Oncol Rep.17(1):35-9.
Zhang SG, Song WQ, Gao YT, Yang B, Du Z.2010. CD1d gene is a target for a novel amplicon at 1q22-23.1 in human hepatocellular carcinoma. Mol Biol Rep; 37(1):381-7.
Zhang YW, Wang LM, Jove R, Vande WGF.2002. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene.21(2):217-26.
Zhong Z, Wen Z, Darnell JE Jr.1994. Stat3:a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science.264(5155): 95-8.
Zhou L, Liu J, Luo F.2006. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol.12(8):1175-81.
Zhou YM, Yang JM, Li B, et al.2010. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int.9(1):33-7.
Zushi S, Shinomura Y, Kiyohara T, et al.1998. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer.78(3):326-30.
潘俊江,杜成友.2004. STAT3、cyclinD1和Bcl-xl在原发性肝癌中的表达及其意义.重庆医科大学硕士论文.
林莉,李小洁,魏晓丽.2007.STAT4的作用机制及其在疾病中的相关研究.细胞与分子免疫学杂志.23(8)：784·86.
Ahuja, S.K., Kulkarni, H., Catano, G., et al. (2008). CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med, 14,413-20.
Aitman, T.J., Dong, R., Vyse, T.J., et al. (2006). Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature,439,851-5.
Andre, F., Job, B., Dessen, P., et al. (2009). Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res, 15,441-51.
Avent, N.D., Martin, P.G., Armstrong-Fisher, S.S., et al. (1997). Evidence of genetic diversity underlying Rh D-, weak D (Du), and partial D phenotypes as determined by multiplex polymerase chain reaction analysis of the RHD gene. Blood,89,2568-77.
Avent, N.D., Reid, M.E. (2000). The Rh blood group system:a review. Blood,95,375-87.
Bacolla, A., Jaworski, A., Larson, J.E., et al. (2004). Breakpoints of gross deletions coincide with non-B DNA conformations. Proc Natl Acad Sci USA,101,14162-7.
Bourdon, V., Plessis, G., Chapon, F., Guarnieri, J., Derlon, J.M., Jonveaux, P. (2004). Chromosome imbalances in oligodendroglial tumors detected by comparative genomic hybridization. Ann Genet,47,105-11.
Bredel, M., Bredel, C., Juric, D., et al. (2005). Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. JMol Diagn,7,171-82.
Bruder, C.E., Piotrowski, A., Gijsbers, A.A., et al. (2008). Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet, 82,763-71.
Calin, G.A., Dumitru, C.D., Shimizu, M., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci US A,99,15524-9.
Cargill, M., Altshuler, D., Ireland, J., et al. (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet,22,231-8.
Carvalho, B., Ouwerkerk, E., Meijer, G.A., Ylstra, B. (2004). High resolution microarray comparative genomic hybridisation analysis using spotted oligonucleotides. J Clin Pathol,57,644-6.
Conrad, D.F., Andrews, T.D., Carter, N.P., Hurles, M.E., Pritchard, J.K. (2006). A high-resolution survey of deletion polymorphism in the human genome. Nat Genet,38,75-81.
Cooper, G.M., Zerr, T., Kidd, J.M., Eichler, E.E., Nickerson, D.A. (2008). Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet,40,1199-203.
Daser, A., Thangavelu, M., Pannell, R., et al. (2006). Interrogation of genomes by molecular copy-number counting (MCC). Nat Methods,3,447-53.
Dear, P.H. (2009). Copy-number variation:the end of the human genome. Trends Biotechnol, 27,448-54.
Deeb, S.S. (2005). The molecular basis of variation in human color vision. Clin Genet,67,369-77.
Derti, A., Roth, F.P., Church, G.M., Wu, C.T. (2006). Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants. Nat Genet, 38,1216-20.
Estivill, X., Armengol, L. (2007). Copy number variants and common disorders:filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet,3,1787-99.
Fanciulli, M., Norsworthy, P.J., Petretto, E., et al. (2007). FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet, 39,721-3.
FERRIER, S. (1964). [MONGOL CHILD-MOSAIC PARENT. STUDY OF 2 FAMILIES.]. J Genet Hum,13,315-36.
Feuk, L., Carson, A.R., Scherer, S.W. (2006). Structural variation in the human genome. Nat Rev Genet,7,85-97.
Feuk, L., Marshall, C.R., Wintle, R.F., Scherer, S.W. (2006). Structural variants:changing the landscape of chromosomes and design of disease studies. Hum Mol Genet,15 Spec No 1,R57-66.
Fielder, A.H., Walport, M.J., Batchelor, J.R., et al. (1983). Family study of the major histocompatibility complex in patients with systemic lupus erythematosus:importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed), 286,425-8.
Flint, J., Harding, R.M., Boyce, A.J., Clegg, J.B. (1998). The population genetics of the haemoglobinopathies. Baillieres Clin Haematol,11,1-51.
Flint, J., Hill, A.V., Bowden, D.K., et al. (1986); High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature,321,744-50.
Fredman, D., White, S.J., Potter, S., Eichler, E.E., Den, D.J.T., Brookes, A.J. (2004). Complex SNP-related sequence variation in segmental genome duplications. Nat Genet,36,861-6.
Gnarra, J.R., Tory, K., Weng, Y., et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet,7,85-90.
Giglio, S., Broman, K.W., Matsumoto, N., et al. (2001). Olfactory receptor-gene clusters, genomic-inversion polymorphisms, and common chromosome rearrangements. Am J Hum Genet,68,874-83.
Giglio, S., Calvari, V., Gregato, G., et al. (2002). Heterozygous submicroscopic inversions involving olfactory receptor-gene clusters mediate the recurrent t(4;8)(p16;p23) translocation. Am J Hum Genet,71,276-85.
Gonzalez, E., Kulkarni, H., Bolivar, H., et al. (2005). The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science,307,1434-40.
Hastings, P.J., Lupski, J.R., Rosenberg, S.M., Ira, G. (2009). Mechanisms of change in gene copy number. Nat Rev Genet,10,551-64.
Hollox, E.J., Armour, J.A., Barber, J.C. (2003). Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet,73,591-600.
Hughes, A.E., Orr, N., Esfandiary, H., Diaz-Torres, M., Goodship, T., Chakravarthy, U. (2006). A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet,38,1173-7.
Hurles, M.E., Dermitzakis, E.T., Tyler-Smith, C. (2008). The functional impact of structural variation in humans. Trends Genet,24,238-45.
Iafrate, A.J., Feuk, L., Rivera, M.N., et al. (2004). Detection of large-scale variation in the human genome. Nat Genet,36,949-51.
Ingelman-Sundberg, M., Sim, S.C., Gomez, A., Rodriguez-Antona, C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies:pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther,116,496-526.
Ionita-Laza, I., Rogers, A.J., Lange, C., Raby, B.A., Lee, C. (2009). Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. Genomics,93,22-6.
Kidd, J.M., Cooper, G.M., Donahue, W.F., et al. (2008). Mapping and sequencing of structural variation from eight human genomes. Nature,453,56-64.
Kleinjan, D.A., van, H.V. (2005). Long-range control of gene expression:emerging mechanisms and disruption in disease. Am JHum Genet,76,8-32.
Komura, D., Shen, F., lshikawa, S., et al. (2006). Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res,16,1575-84.
Kurahashi, H., Emanuel, B.S. (2001). Long AT-rich palindromes and the constitutional t(11;22) breakpoint. Hum Mol Genet,10,2605-17.
Lee, J.A., Carvalho, C.M., Lupski, J.R. (2007). A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell,131,1235-47.
Lee, J.A., Madrid, R.E., Sperle, K., et al. (2006). Spastic paraplegia type 2 associated with axonal neuropathy and apparent PLP1 position effect. Ann Neurol,59,398-403.
LEJEUNE, J., TURPIN, R., GAUTIER, M. (1959). [Mongolism; a chromosomal disease (trisomy).]. Bull Acad Natl Med,143,256-65.
Li, J., Yang, T., Wang, L., et al. (2009). Whole genome distribution and ethnic differentiation of copy number variation in Caucasian and Asian populations. PLoS One,4,e7958.
Little, S.E., Vuononvirta, R., Reis-Filho, J.S., et al. (2006). Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics, 87,298-306.
Lupski, J.R. (2007). Genomic rearrangements and sporadic disease. Nat Genet,39,S43-7.
Lupski, J.R., Stankiewicz, P. (2005). Genomic disorders:molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet,1,e49.
McCarroll, S.A. (2008). Extending genome-wide association studies to copy-number variation. Hum Mol Genet,17,R135-42.
McCarroll, S.A., Hadnott, T.N., Perry, G.H., et al. (2006). Common deletion polymorphisms in the human genome. Nat Genet,38,86-92.
McCarroll, S.A., Huett, A., Kuballa, P., et al. (2008). Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet,40,1107-12.
McCarroll, S.A., Kuruvilla, F.G., Korn, J.M., et al. (2008). Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet,40,1166-74.
McCaughan, F., Darai-Ramqvist, E., Bankier, A.T., et al. (2008). Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR. J Pathol, 216,307-16.
Nakamura, Y. (2009). DNA variations in human and medical genetics:25 years of my experience. J Hum Genet,54,1-8.
Perry, G.H., Dominy, N.J., Claw, K.G., et al. (2007). Diet and the evolution of human amylase gene copy number variation. Nat Genet,39,1256-60.
Piotrowski, A., Bruder, C.E., Andersson, R., et al. (2008). Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat,29,1118-24.
Redon, R., Ishikawa, S., Fitch, K.R., et al. (2006). Global variation in copy number in the human genome. Nature,444,444-54.
Rittinger,0., Kronberger, G., Pfeifenberger, A., Kotzot, D., Fauth, C. (2008). The changing phenotype in diploid/triploid mosaicism may mimic genetic syndromes with aberrant genomic imprinting: follow up in a 14-year-old girl. Eur J Med Genet,51,573-9.
Sachidanandam, R., Weissman, D., Schmidt, S.C., et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature,409,928-33.
Saxena, R., Voight, B.F., Lyssenko, V., et al. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science,316,1331-6.
Schaschl, H., Aitman, T.J., Vyse, T.J. (2009). Copy number variation in the human genome and its implication in autoimmunity. Clin Exp Immunol,156,12-6.
Schouten, J.P., McElgunn, C.J., Waaijer, R., Zwijnenburg, D., Diepvens, F., Pals, G. (2002). Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res,30,e57.
Sebat, J., Lakshmi, B., Troge, J., et al. (2004). Large-scale copy number polymorphism in the human genome. Science,305,525-8.
Shaw-Smith, C., Redon, R., Rickman, L., et al. (2004). Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet, 41,241-8.
Shendure, J., Mitra, R.D., Varma, C., Church, G.M. (2004). Advanced sequencing technologies: methods and goals. Nat Rev Genet,5,335-44.
Shlien, A., Malkin, D. (2010). Copy number variations and cancer susceptibility. Curr Opin Oncol, 22,55-63.
Shlien, A., Tabori, U., Marshall, C.R., et al. (2008). Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA,105,11264-9.
Spencer, K.L., Hauser, M.A., Olson, L.M., et al. (2008). Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. Hum Mol Genet,17,971-7.
Stranger, B.E., Forrest, M.S., Dunning, M., et al. (2007). Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science,315,848-53.
Sugawara, H., Harada, N., Ida, T., et al. (2003). Complex low-copy repeats associated with a common polymorphic inversion at human chromosome 8p23. Genomics,82,238-44.
Sussan, T.E., Yang, A., Li, F., Ostrowski, M.C., Reeves, R.H. (2008). Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature,451,73-5.
Tonon, G., Brennan, C., Protopopov, A., et al. (2005). Common and contrasting genomic profiles among the major human lung cancer subtypes. Cold Spring Harb Symp Quant Biol,70,11-24.
Townson, J.R., Barcellos, L.F., Nibbs, R.J. (2002). Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol,32,3016-26.
Tuzun, E., Sharp, A.J., Bailey, J.A., et al. (2005). Fine-scale structural variation of the human genome. Nat Genet,37,727-32.
van, B.E.H., Joosse, S.A., Ligtenberg, M.J., et al. (2006). A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer,94,333-7.
Vissers, L.E., Veltman, J.A., van, K.A.G., Brunner, H.G. (2005). Identification of disease genes by whole genome CGH arrays. Hum Mol Genet,14 Spec No.2,R215-23.
Wain, L.V., Armour, J.A., Tobin, M.D. (2009). Genomic copy number variation, human health, and disease. Lancet,374,340-50.
Westra, J.W., Peterson, S.E., Yung, Y.C., Mutoh, T., Barral, S., Chun, J. (2008). Aneuploid mosaicism in the developing and adult cerebellar cortex. J Comp Neurol,507,1944-51.
Wong, K.K., deLeeuw, R.J., Dosanjh, N.S., et al. (2007). A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet,80,91-104.
Xu, B., Roos, J.L., Levy, S., van, R.E.J., Gogos, J.A., Karayiorgou, M. (2008). Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet,40,880-5.
Yang, A.H., Kaushal, D., Rehen, S.K., et al. (2003). Chromosome segregation defects contribute to aneuploidy in normal neural progenitor cells. J Neurosci,23,10454-62.
Yang, T.L., Chen, X.D., Guo, Y., et al. (2008). Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet,83,663-74.
Yang, Y., Chung, E.K., Wu, Y.L., et al. (2007). Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am JHum Genet,80,1037-54.
Yim, S.H., Kim, T.M., Hu, H.J., et al. (2010). Copy number variations in East-Asian population and their evolutionary and functional implications. Hum Mol Genet,19,1001-8.
Zipfel, P.F., Edey, M., Heinen, S., et al. (2007). Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet, 3,e41.
胡彬,陈军,刘红雨等.(2008).利用单核苷酸多态性芯片全基因组检测人大细胞肺癌细胞株的杂合性缺失和拷贝数变异.中国肺癌杂志,327-332.
孙玉琳,刘飞,赵晓航。(2009).拷贝数变异的全基因组关联研究.生物化学与生物物理进展,663-674.
谭琪,曾凡一.(2009).遗传变异的又一来源——拷贝数变异.生物技术通讯,396-398.
吴志俊,金玮.(2009).拷贝数变异：基因组多样性的新形式.遗传,339-347.
严卫丽.(2008).复杂疾病全基因组关联研究进展——研究设计和遗传标记.遗传,400-406.
Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al.2009. Signal transducer and activator of transcription-3, inflammation, and cancer:how intimate is the relationship. Ann N Y Acad Sci. 1171:59-76.
Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB.2008. Guggulsterone, a famesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res.68(11):4406-15.
Ahuja SK, Kulkarni H, Catano G, et al.2008. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med.14(4): 413-20.
Aitman TJ, Dong R, Vyse TJ, et al.2006. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature.439(7078):851-5.
Aoki Y, Feldman GM, Tosato G.2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood.101(4):1535-42.
Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA.2006. Receptor-mediated tobacco toxicity:cooperation of the Ras/Raf-1/MEKl/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J.20(12):2093-101.
Banninger G, Reich NC.2004. STAT2 nuclear trafficking. J Biol Chem.279(38):39199-206.
Bao BY, Hu YC, Ting HJ, Lee YF.2004. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene.23(19):3350-60.
Bharti AC, Shishodia S, Reuben JM, et al.2004. Nuclear factor-kappaB and STAT3 are constitutively active in CD 138+cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood.103(8):3175-84.
Bhattacharya S, Schindler C.2003. Regulation of Stat3 nuclear export. J Clin Invest.111(4):553-9.
Bianchini F, Mannini A, Mugnai G, Ruggieri S, Calorini L.2006. Expression of a metastatic phenotype in IFNs-primed/TNFalpha-activated B16 murine melanoma cells:role of JAKl/PKCdelta signal transduction factors. Clin Exp Metastasis.23(3-4):203-8.
Bluyssen AR, Durbin JE, Levy DE.1996. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev.7(1):11-7.
Boehm AL, Sen M, Seethala R, et al.2008. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol.73(6):1632-42.
Bosch FX, Ribes J, Cleries R, Diaz M.2005. Epidemiology of hepatocellular carcinoma. Clin Liver Dis.9(2):191-211.
Bot A, Rodrigo E, Wolfe T, Bot S, Von Herrath MG.2003. Infection-triggered regulatory mechanisms override the role of STAT 4 in control of the immune response to influenza virus antigens. J Virol.77(10):5794-800.
Bowman T, Garcia R, Turkson J, Jove R.2000. STATs in oncogenesis. Oncogene.19(21):2474-88.
Bromberg J, Darnell JE Jr.2000. The role of STATs in transcriptional control and their impact on cellular function. Oncogene.19(21):2468-73.
Catlett-Falcone R, Landowski TH, Oshiro MM, et al.1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity.10(1):105-15.
Chan KS, Sano S, Kataoka K, et al.2008. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene.27(8):1087-94.
Chan KS, Sano S, Kiguchi K, et al.2004. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest.114(5):720-8.
Chen L, Chan TH, Yuan YF, et al.2010. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 120(4):1178-91.
Cheng GZ, Zhang WZ, Sun M, et al.2008. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem.283(21):14665-73.
Chung CD, Liao J, Liu B, et al.1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science.278(5344):1803-5.
Chung J, Uchida E, Grammer TC, Blenis J.1997. STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 17(11):6508-16.
Cucchetti A, Piscaglia F, Grigioni AD, et al.2010. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network:A pilot study. J Hepatol.
Darnell JE Jr.1997. STATs and gene regulation. Science.277(5332):1630-5.
Darnell JE Jr, Kerr IM, Stark GR.1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science.264(5164):1415-21.
Dear PH.2009. Copy-number variation:the end of the human genome. Trends Biotechnol.27(8): 448-54.
El-Zayadi AR.2006. Heavy smoking and liver. World J Gastroenterol.12(38):6098-101.
Elinav E, Abd-Elnabi A, Pappo O, et al.2006. Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumor cell growth and natural killer cell activation. J Hepatol.44(3):529-36.
Estivill X, Armengol L.2007. Copy number variants and common disorders:filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet.3(10):1787-99.
Fanciulli M, Norsworthy PJ, Petretto E, et al.2007. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet.39(6):721-3.
Frank DA.2007. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251(2):199-210.
Garcia R, Yu CL, Hudnall A, et al.1997. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ.8(12):1267-76.
Gonzalez E, Kulkarni H, Bolivar H, et al.2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science.307(5714):1434-40.
Grunhage F, Nattermann J, Gressner OA, et al.2010. Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C. J Hepatol.52(2):153-9.
Guo Y, Chen Y, Ito H, et al.2006. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene.384:51-61.
Hayashi T, Kobayashi Y, Kohsaka S, Sano K 2006. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene.25(29):4016-26.
Hurles ME, Dermitzakis ET, Tyler-Smith C.2008. The functional impact of structural variation in humans. Trends Genet.24(5):238-45.
Ihle JN.1996. STATs:signal transducers and activators of transcription. Cell.84(3):331-4.
Itoh M, Murata T, Suzuki T, et al.2006. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene.25(8):1195-204.
Ivanov VN, Bhoumik A, Krasilnikov M, et al.2001. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell.7(3):517-28.
Ji J, Shi J, Budhu A, et al.2009. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med.361(15):1437-47.
Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ.2004. G-quartet oligonucleotides:a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res.64(18):6603-9.
Ju MJ, Qiu SJ, Fan J, et al.2009. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol.131(4): 498-510.
Kanda N, Seno H, Konda Y, et al.2004. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene.23(28):4921-9.
Karni R, Jove R, Levitzki A.1999. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 18(33):4654-62.
Kataoka K, Kim DJ, Carbajal S, Clifford JL, DiGiovanni J.2008. Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis.29(6):1108-14.
Kim KW, Mutter RW, Cao C, et al.2006. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther.5(11): 2659-65.
Kiuchi N, Nakajima K, Ichiba M, et al.1999. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med.189(1):63-73.
Klein C, Wustefeld T, Assmus U, et al.2005. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest.115(4):860-9.
Kleinjan DA, van HV.2005. Long-range control of gene expression:emerging mechanisms and disruption in disease. Am J Hum Genet.76(1):8-32.
Kobierski LA, Srivastava S, Borsook D.2000. Systemic lipopolysaccharide and interleukin-Ibeta activate the interleukin 6:STAT intracellular signaling pathway in neurons of mouse trigeminal ganglion. Neurosci Lett.281(1):61-4.
Komura D, Shen F, Ishikawa S, et al.2006. Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res.16(12):1575-84.
Lee JS, Chu IS, Heo J, et al.2004. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology.40(3):667-76.
Lee JS, Heo J, Libbrecht L, et al.2006. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med.12(4):410-6.
Lee JS.2008. Decoding human liver cancer signatures. Gastrointest Cancer Res.2(4 Suppl):S31-4.
Li W, Tan D, Zenali MJ, Brown RE.2010. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol.3(3): 238-43.
Liu H, Ma Y, Cole SM, et al.2003. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood.102(1):344-52.
Llovet JM, Burroughs A, Bruix J.2003. Hepatocellular carcinoma. Lancet.362(9399):1907-17.
Lou YJ, Pan XR, Jia PM, et al.2009. IRF-9/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1. Cancer Res.69(8):3673-80.
Mahboubi K, Li F, Plescia J, et al.2001. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest.81(3):327-34.
Masuda M, Suzui M, Yasumatu R, et al.2002. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res.62(12):3351-5.
McCarroll SA, Hadnott TN, Perry GH, et al.2006. Common deletion polymorphisms in the human genome. Nat Genet.38(1):86-92.
McCarroll SA, Huett A, Kuballa P, et al.2008. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet.40(9):1107-12.
McCarroll SA, Kuruvilla FG, Korn JM, et al.2008. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet.40(10):1166-74.
Neilson LM, Zhu J, Xie J, et al.2007. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer:recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol.21(9):2218-32.
Nieters A, Yuan JM, Sun CL, et al.2005. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer.103(4):740-8.
Nikitakis NG, Siavash H, Sauk JJ.2004. Targeting the STAT pathway in head and neck cancer:recent advances and future prospects. Curr Cancer Drug Targets.4(8):637-51.
Niu G, Wright KL, Huang.M, et al.2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene.21(13):2000-8.
Noda I, Fujieda S, Ohtsubo T, et al.1999. Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer.80(1):78-84.
Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC.2009. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 30(5):758-62.
Otero DC, Poli V, David M, Rickert RC.2006. Cutting edge:inherent and acquired resistance to radiation-induced apoptosis in B cells:a pivotal role for STAT3. J Immunol.177(10):6593-7.
Parkin DM, Bray F, Ferlay J, Pisani P.2005. Global cancer statistics,2002. CA Cancer J Clin.55(2): 74-108.
Piva R, Gambari R.2002. Transcription factor decoy (TFD) in breast cancer research and treatment. Technol Cancer Res Treat.1(5):405-16.
Rane SG, Reddy EP.2000. Janus kinases:components of multiple signaling pathways. Oncogene. 19(49):5662-79.
Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL.2002. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene.21(50):7611-8.
Redon R, Ishikawa S, Fitch KR, et al.2006. Global variation in copy number in the human genome. Nature.444(7118):444-54.
Rhodes DR, Yu J, Shanker K, et al.2004. ONCOMINE:a cancer microarray database and integrated data-mining platform. Neoplasia.6(1):1-6.
Rossi MR, Hawthorn L, Platt J, Burkhardt T, Cowell JK, Ionov Y.2005. Identification of inactivating mutations in the JAKl, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet.161(2):97-103.
Saito H, Masuda T, Tada S, et al.2009. Hepatocellular carcinoma in Keio affiliated hospitals-diagnosis, treatment, and prognosis of this disease. Keio J Med.58(3):161-75.
Saxena R, Voight BF, Lyssenko V, et al.2007. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science.316(5829):1331-6.
Shang D, Liu Y, Ito N, Kamoto T, Ogawa O.2007. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci.98(8):1259-64.
Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T.1999. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity.11(6): 709-19.
Shlien A, Tabori U, Marshall CR, et al.2008. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A.105(32):11264-9.
Singh N, Ebrahimi FA, Gimelbrant AA, et al.2003. Coordination of the random asynchronous replication of autosomal loci. Nat Genet.33(3):339-41.
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A.2010. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol.16(4):418-24.
Stranger BE, Forrest MS, Dunning M, et al.2007. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science.315(5813):848-53.
Suiqing C, Min Z, Lirong C.2005. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol.32(5):354-60.
Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH.2008. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature.451(7174):73-5.
Townson JR, Barcellos LF, Nibbs RJ.2002. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol.32(10):3016-26.
Vainchenker W, Dusa A, Constantinescu SN.2008. JAKs in pathology:role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol.19(4):385-93.
Verma A, Kambhampati S, Parmar S, Platanias LC.2003. Jak family of kinases in cancer. Cancer Metastasis Rev.22(4):423-34.
Viswanathan SR, Powers JT, Einhom W, et al.2009. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet.41(7):843-8.
Wang T, Niu G, Kortylewski M, et al.2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med.10(1):48-54.
Wei D, Le X, Zheng L, et al.2003. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene.22(3): 319-29.
Yao DF, Dong ZZ, Yao M.2007. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.6(3):241-7.
Yeh YT, Ou-Yang F, Chen IF, et al.2007. Altered p-JAKl expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma. Oncol Rep.17(1):35-9.
Zhang SG, Song WQ, Gao YT, Yang B, Du Z.2010. CD1d gene is a target for a novel amplicon at 1q22-23.1 in human hepatocellular carcinoma. Mol Biol Rep; 37(1):381-7.
Zhang YW, Wang LM, Jove R, Vande WGF.2002. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene.21(2):217-26.
Zhong Z, Wen Z, Darnell JE Jr.1994. Stat3:a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science.264(5155): 95-8.
Zhou L, Liu J, Luo F.2006. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol.12(8):1175-81.
Zhou YM, Yang JM, Li B, et al.2010. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int.9(1):33-7.
Zushi S, Shinomura Y, Kiyohara T, et al.1998. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer.78(3):326-30.
潘俊江,杜成友.2004. STAT3、cyclinD1和Bcl-xl在原发性肝癌中的表达及其意义.重庆医科大学硕士论文.
林莉,李小洁,魏晓丽.2007.STAT4的作用机制及其在疾病中的相关研究.细胞与分子免疫学杂志.23(8)：784·86.
Ahuja, S.K., Kulkarni, H., Catano, G., et al. (2008). CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med, 14,413-20.
Aitman, T.J., Dong, R., Vyse, T.J., et al. (2006). Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature,439,851-5.
Andre, F., Job, B., Dessen, P., et al. (2009). Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res, 15,441-51.
Avent, N.D., Martin, P.G., Armstrong-Fisher, S.S., et al. (1997). Evidence of genetic diversity underlying Rh D-, weak D (Du), and partial D phenotypes as determined by multiplex polymerase chain reaction analysis of the RHD gene. Blood,89,2568-77.
Avent, N.D., Reid, M.E. (2000). The Rh blood group system:a review. Blood,95,375-87.
Bacolla, A., Jaworski, A., Larson, J.E., et al. (2004). Breakpoints of gross deletions coincide with non-B DNA conformations. Proc Natl Acad Sci USA,101,14162-7.
Bourdon, V., Plessis, G., Chapon, F., Guarnieri, J., Derlon, J.M., Jonveaux, P. (2004). Chromosome imbalances in oligodendroglial tumors detected by comparative genomic hybridization. Ann Genet,47,105-11.
Bredel, M., Bredel, C., Juric, D., et al. (2005). Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. JMol Diagn,7,171-82.
Bruder, C.E., Piotrowski, A., Gijsbers, A.A., et al. (2008). Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet, 82,763-71.
Calin, G.A., Dumitru, C.D., Shimizu, M., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci US A,99,15524-9.
Cargill, M., Altshuler, D., Ireland, J., et al. (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet,22,231-8.
Carvalho, B., Ouwerkerk, E., Meijer, G.A., Ylstra, B. (2004). High resolution microarray comparative genomic hybridisation analysis using spotted oligonucleotides. J Clin Pathol,57,644-6.
Conrad, D.F., Andrews, T.D., Carter, N.P., Hurles, M.E., Pritchard, J.K. (2006). A high-resolution survey of deletion polymorphism in the human genome. Nat Genet,38,75-81.
Cooper, G.M., Zerr, T., Kidd, J.M., Eichler, E.E., Nickerson, D.A. (2008). Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet,40,1199-203.
Daser, A., Thangavelu, M., Pannell, R., et al. (2006). Interrogation of genomes by molecular copy-number counting (MCC). Nat Methods,3,447-53.
Dear, P.H. (2009). Copy-number variation:the end of the human genome. Trends Biotechnol, 27,448-54.
Deeb, S.S. (2005). The molecular basis of variation in human color vision. Clin Genet,67,369-77.
Derti, A., Roth, F.P., Church, G.M., Wu, C.T. (2006). Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants. Nat Genet, 38,1216-20.
Estivill, X., Armengol, L. (2007). Copy number variants and common disorders:filling the gaps and exploring complexity in genome-wide association studies. PLoS Genet,3,1787-99.
Fanciulli, M., Norsworthy, P.J., Petretto, E., et al. (2007). FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet, 39,721-3.
FERRIER, S. (1964). [MONGOL CHILD-MOSAIC PARENT. STUDY OF 2 FAMILIES.]. J Genet Hum,13,315-36.
Feuk, L., Carson, A.R., Scherer, S.W. (2006). Structural variation in the human genome. Nat Rev Genet,7,85-97.
Feuk, L., Marshall, C.R., Wintle, R.F., Scherer, S.W. (2006). Structural variants:changing the landscape of chromosomes and design of disease studies. Hum Mol Genet,15 Spec No 1,R57-66.
Fielder, A.H., Walport, M.J., Batchelor, J.R., et al. (1983). Family study of the major histocompatibility complex in patients with systemic lupus erythematosus:importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed), 286,425-8.
Flint, J., Harding, R.M., Boyce, A.J., Clegg, J.B. (1998). The population genetics of the haemoglobinopathies. Baillieres Clin Haematol,11,1-51.
Flint, J., Hill, A.V., Bowden, D.K., et al. (1986); High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature,321,744-50.
Fredman, D., White, S.J., Potter, S., Eichler, E.E., Den, D.J.T., Brookes, A.J. (2004). Complex SNP-related sequence variation in segmental genome duplications. Nat Genet,36,861-6.
Gnarra, J.R., Tory, K., Weng, Y., et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet,7,85-90.
Giglio, S., Broman, K.W., Matsumoto, N., et al. (2001). Olfactory receptor-gene clusters, genomic-inversion polymorphisms, and common chromosome rearrangements. Am J Hum Genet,68,874-83.
Giglio, S., Calvari, V., Gregato, G., et al. (2002). Heterozygous submicroscopic inversions involving olfactory receptor-gene clusters mediate the recurrent t(4;8)(p16;p23) translocation. Am J Hum Genet,71,276-85.
Gonzalez, E., Kulkarni, H., Bolivar, H., et al. (2005). The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science,307,1434-40.
Hastings, P.J., Lupski, J.R., Rosenberg, S.M., Ira, G. (2009). Mechanisms of change in gene copy number. Nat Rev Genet,10,551-64.
Hollox, E.J., Armour, J.A., Barber, J.C. (2003). Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet,73,591-600.
Hughes, A.E., Orr, N., Esfandiary, H., Diaz-Torres, M., Goodship, T., Chakravarthy, U. (2006). A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet,38,1173-7.
Hurles, M.E., Dermitzakis, E.T., Tyler-Smith, C. (2008). The functional impact of structural variation in humans. Trends Genet,24,238-45.
Iafrate, A.J., Feuk, L., Rivera, M.N., et al. (2004). Detection of large-scale variation in the human genome. Nat Genet,36,949-51.
Ingelman-Sundberg, M., Sim, S.C., Gomez, A., Rodriguez-Antona, C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies:pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther,116,496-526.
Ionita-Laza, I., Rogers, A.J., Lange, C., Raby, B.A., Lee, C. (2009). Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. Genomics,93,22-6.
Kidd, J.M., Cooper, G.M., Donahue, W.F., et al. (2008). Mapping and sequencing of structural variation from eight human genomes. Nature,453,56-64.
Kleinjan, D.A., van, H.V. (2005). Long-range control of gene expression:emerging mechanisms and disruption in disease. Am JHum Genet,76,8-32.
Komura, D., Shen, F., lshikawa, S., et al. (2006). Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res,16,1575-84.
Kurahashi, H., Emanuel, B.S. (2001). Long AT-rich palindromes and the constitutional t(11;22) breakpoint. Hum Mol Genet,10,2605-17.
Lee, J.A., Carvalho, C.M., Lupski, J.R. (2007). A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell,131,1235-47.
Lee, J.A., Madrid, R.E., Sperle, K., et al. (2006). Spastic paraplegia type 2 associated with axonal neuropathy and apparent PLP1 position effect. Ann Neurol,59,398-403.
LEJEUNE, J., TURPIN, R., GAUTIER, M. (1959). [Mongolism; a chromosomal disease (trisomy).]. Bull Acad Natl Med,143,256-65.
Li, J., Yang, T., Wang, L., et al. (2009). Whole genome distribution and ethnic differentiation of copy number variation in Caucasian and Asian populations. PLoS One,4,e7958.
Little, S.E., Vuononvirta, R., Reis-Filho, J.S., et al. (2006). Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics, 87,298-306.
Lupski, J.R. (2007). Genomic rearrangements and sporadic disease. Nat Genet,39,S43-7.
Lupski, J.R., Stankiewicz, P. (2005). Genomic disorders:molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet,1,e49.
McCarroll, S.A. (2008). Extending genome-wide association studies to copy-number variation. Hum Mol Genet,17,R135-42.
McCarroll, S.A., Hadnott, T.N., Perry, G.H., et al. (2006). Common deletion polymorphisms in the human genome. Nat Genet,38,86-92.
McCarroll, S.A., Huett, A., Kuballa, P., et al. (2008). Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet,40,1107-12.
McCarroll, S.A., Kuruvilla, F.G., Korn, J.M., et al. (2008). Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet,40,1166-74.
McCaughan, F., Darai-Ramqvist, E., Bankier, A.T., et al. (2008). Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR. J Pathol, 216,307-16.
Nakamura, Y. (2009). DNA variations in human and medical genetics:25 years of my experience. J Hum Genet,54,1-8.
Perry, G.H., Dominy, N.J., Claw, K.G., et al. (2007). Diet and the evolution of human amylase gene copy number variation. Nat Genet,39,1256-60.
Piotrowski, A., Bruder, C.E., Andersson, R., et al. (2008). Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat,29,1118-24.
Redon, R., Ishikawa, S., Fitch, K.R., et al. (2006). Global variation in copy number in the human genome. Nature,444,444-54.
Rittinger,0., Kronberger, G., Pfeifenberger, A., Kotzot, D., Fauth, C. (2008). The changing phenotype in diploid/triploid mosaicism may mimic genetic syndromes with aberrant genomic imprinting: follow up in a 14-year-old girl. Eur J Med Genet,51,573-9.
Sachidanandam, R., Weissman, D., Schmidt, S.C., et al. (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature,409,928-33.
Saxena, R., Voight, B.F., Lyssenko, V., et al. (2007). Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science,316,1331-6.
Schaschl, H., Aitman, T.J., Vyse, T.J. (2009). Copy number variation in the human genome and its implication in autoimmunity. Clin Exp Immunol,156,12-6.
Schouten, J.P., McElgunn, C.J., Waaijer, R., Zwijnenburg, D., Diepvens, F., Pals, G. (2002). Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res,30,e57.
Sebat, J., Lakshmi, B., Troge, J., et al. (2004). Large-scale copy number polymorphism in the human genome. Science,305,525-8.
Shaw-Smith, C., Redon, R., Rickman, L., et al. (2004). Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet, 41,241-8.
Shendure, J., Mitra, R.D., Varma, C., Church, G.M. (2004). Advanced sequencing technologies: methods and goals. Nat Rev Genet,5,335-44.
Shlien, A., Malkin, D. (2010). Copy number variations and cancer susceptibility. Curr Opin Oncol, 22,55-63.
Shlien, A., Tabori, U., Marshall, C.R., et al. (2008). Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA,105,11264-9.
Spencer, K.L., Hauser, M.A., Olson, L.M., et al. (2008). Deletion of CFHR3 and CFHR1 genes in age-related macular degeneration. Hum Mol Genet,17,971-7.
Stranger, B.E., Forrest, M.S., Dunning, M., et al. (2007). Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science,315,848-53.
Sugawara, H., Harada, N., Ida, T., et al. (2003). Complex low-copy repeats associated with a common polymorphic inversion at human chromosome 8p23. Genomics,82,238-44.
Sussan, T.E., Yang, A., Li, F., Ostrowski, M.C., Reeves, R.H. (2008). Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature,451,73-5.
Tonon, G., Brennan, C., Protopopov, A., et al. (2005). Common and contrasting genomic profiles among the major human lung cancer subtypes. Cold Spring Harb Symp Quant Biol,70,11-24.
Townson, J.R., Barcellos, L.F., Nibbs, R.J. (2002). Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol,32,3016-26.
Tuzun, E., Sharp, A.J., Bailey, J.A., et al. (2005). Fine-scale structural variation of the human genome. Nat Genet,37,727-32.
van, B.E.H., Joosse, S.A., Ligtenberg, M.J., et al. (2006). A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer,94,333-7.
Vissers, L.E., Veltman, J.A., van, K.A.G., Brunner, H.G. (2005). Identification of disease genes by whole genome CGH arrays. Hum Mol Genet,14 Spec No.2,R215-23.
Wain, L.V., Armour, J.A., Tobin, M.D. (2009). Genomic copy number variation, human health, and disease. Lancet,374,340-50.
Westra, J.W., Peterson, S.E., Yung, Y.C., Mutoh, T., Barral, S., Chun, J. (2008). Aneuploid mosaicism in the developing and adult cerebellar cortex. J Comp Neurol,507,1944-51.
Wong, K.K., deLeeuw, R.J., Dosanjh, N.S., et al. (2007). A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet,80,91-104.
Xu, B., Roos, J.L., Levy, S., van, R.E.J., Gogos, J.A., Karayiorgou, M. (2008). Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet,40,880-5.
Yang, A.H., Kaushal, D., Rehen, S.K., et al. (2003). Chromosome segregation defects contribute to aneuploidy in normal neural progenitor cells. J Neurosci,23,10454-62.
Yang, T.L., Chen, X.D., Guo, Y., et al. (2008). Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet,83,663-74.
Yang, Y., Chung, E.K., Wu, Y.L., et al. (2007). Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am JHum Genet,80,1037-54.
Yim, S.H., Kim, T.M., Hu, H.J., et al. (2010). Copy number variations in East-Asian population and their evolutionary and functional implications. Hum Mol Genet,19,1001-8.
Zipfel, P.F., Edey, M., Heinen, S., et al. (2007). Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet, 3,e41.
胡彬,陈军,刘红雨等.(2008).利用单核苷酸多态性芯片全基因组检测人大细胞肺癌细胞株的杂合性缺失和拷贝数变异.中国肺癌杂志,327-332.
孙玉琳,刘飞,赵晓航。(2009).拷贝数变异的全基因组关联研究.生物化学与生物物理进展,663-674.
谭琪,曾凡一.(2009).遗传变异的又一来源——拷贝数变异.生物技术通讯,396-398.
吴志俊,金玮.(2009).拷贝数变异：基因组多样性的新形式.遗传,339-347.
严卫丽.(2008).复杂疾病全基因组关联研究进展——研究设计和遗传标记.遗传,400-406.